Your browser doesn't support javascript.
loading
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.
Merle, Philippe; Kudo, Masatoshi; Edeline, Julien; Bouattour, Mohamed; Cheng, Ann-Lii; Chan, Stephen L; Yau, Thomas; Garrido, Marcelo; Knox, Jennifer; Daniele, Bruno; Breder, Valeriy; Lim, Ho Yeong; Ogasawara, Sadahisa; Cattan, Stéphane; Chao, Yee; Siegel, Abby B; Martinez-Forero, Iván; Wei, Ziwen; Liu, Chih-Chin; Finn, Richard S.
Afiliação
  • Merle P; Department of Hepatology and Gastroenterology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, and Centre de Recherche en Cancerologie de Lyon, Lyon, France.
  • Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Edeline J; INSERM, University Rennes, Department of Medical Oncology, CLCC Eugène Marquis, COSS (Chemistry Oncogenesis Stress Signaling) - UMR_S 1242, Rennes, France.
  • Bouattour M; Department of Liver Cancer Unit, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, France.
  • Cheng AL; Department of Medical Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
  • Chan SL; Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China.
  • Yau T; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Garrido M; Department of Medical Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile.
  • Knox J; Department of Medical Oncology, UHN Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Daniele B; Department of Oncology, Ospedale del Mare, Naples, Italy.
  • Breder V; Department of Chemotherapy, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.
  • Lim HY; Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Cattan S; Department of Medical Oncology and Gastroenterology, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
  • Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Siegel AB; Department of Medical Oncology, Merck & Co., Inc., Rahway, NJ, USA.
  • Martinez-Forero I; Department of Medical Oncology, MSD, Luzern, Switzerland.
  • Wei Z; Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
  • Liu CC; Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
  • Finn RS; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Liver Cancer ; 12(4): 309-320, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37901200
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Liver Cancer Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Liver Cancer Ano de publicação: 2023 Tipo de documento: Article